natgillin/translations-raw huggingface dataset:
The pharmacokinetics of tenofovir following a 245 mg dose of tenofovir disoproxil have been studied in healthy subjects with moderate to severe hepatic impairment. 
Dizoproksiltenofovirat Farmakokinetiko tenofovirja po odmerku 245 mg dizoproksiltenofovirata so raziskali pri zdravih osebah z zmerno do hudo okvaro jeter.
Pharmacokinetic parameters were not altered by diminishing hepatic function. 
Zmanjšanje delovanja jeter ni spremenilo farmakokinetičnih parametrov.
Delstrigo is indicated for the treatment of adults infected with HIV-1 without past or present evidence of resistance to the NNRTI class, lamivudine, or tenofovir (see sections 4.4 and 5.1). 
Zdravilo Delstrigo je indicirano za zdravljenje odraslih, okuženih s HIV-1, ki nimajo in tudi nikoli niso imeli znakov odpornosti proti nenukleozidnim zaviralcem reverzne transkriptaze (NNRTI), lamivudinu ali tenofovirju (glejte poglavji 4.4 in 5.1).
It is preferable to avoid the use of Delstrigo during pregnancy. 
Iz previdnosti se je uporabi zdravila Delstrigo med nosečnostjo bolje izogniti.
After multiple-dose oral administration of lamivudine 300 mg once daily for 7 days to 60 healthy subjects, steady-state Cmax (Cmax,ss) was 2.04 ± 0.54 mcg per mL (mean ± SD) and the 24-hour steady-state AUC (AUC24,ss) was 8.87 ± 1.83 mcg•hour per mL. 
Po uporabi večkratnih peroralnih odmerkov 300 mg lamivudina enkrat na dan 7 dni pri 60 zdravih osebah je bila Cmax v stanju dinamičnega ravnovesja (Cmax,ss) 2,04 ± 0,54 mikrograma na ml (povprečje ± standardni odklon), in 24-urna AUC v stanju dinamičnega ravnovesja (AUC24,ss) 8,87 ± 1,83 mikrograma•ura na ml. Vezava na beljakovine v plazmi je majhna.
• thioridazine (a medicine to treat psychiatric conditions such as schizophrenia) 
• tioridazin (zdravilo za zdravljenje psihiatričnih motenj, na primer shizofrenije).
Subjects must have been virologically suppressed (HIV-1 RNA < 40 copies/mL) on their baseline regimen for at least 6 months prior to trial entry, with no history of virologic failure, and a documented absence of RT substitutions conferring resistance to doravirine, lamivudine and tenofovir (see section, Resistance). 
Preiskovanci so morali biti med uporabo svoje izhodiščne sheme virološko suprimirani (HIV-1 RNA < 40 kopij/ml) vsaj 6 mesecev pred vključitvijo v preskušanje, v anamnezi niso smeli imeti virološkega neuspeha in so morali imeti potrjeno odsotnost substitucij RT, ki povzročajo odpornost proti doravirinu, lamivudinu in tenofovirju (glejte poglavje Odpornost).
Studies in pregnant rats and rabbits showed that doravirine is transferred to the foetus through the placenta, with foetal plasma concentrations of up to 40 % (rabbits) and 52 % (rats) that of maternal concentrations observed on gestation Day 20. 
Rezultati študije pri brejih podganah in kunkah so pokazali, da doravirin prehaja v plod skozi placento; 20. dan gestacije je bila koncentracija v plodovi plazmi do 40 % (kunci) oz. 52 % (podgane) koncentracije pri materi.
Effects of doravirine, lamivudine, and tenofovir disoproxil on other medicinal products Doravirine 
Vpliv doravirina, lamivudina in dizoproksiltenofovirata na druga zdravila
Lamivudine Lamivudine did not affect male or female fertility in rats. 
Lamivudin Lamivudin ni vplival na plodnost podganjih samcev in samic.
• inflammation of the skin due to allergy, redness on the cheeks, nose, chin or forehead, bumps or pimples on the face, swelling of the face, lips, tongue or throat 
• vnetje kože zaradi alergije, pordelost lic, nosu, brade ali čela, bulice ali mozolji na obrazu,
Doravirine does not inhibit the human cellular DNA polymerases α, ß, and mitochondrial DNA polymerase γ. 
Doravirin ne zavira človeških celičnih DNA polimeraz α in β ali mitohondrijske DNA polimeraze γ.
• mitotane 
• mitotan,
• ledipasvir/sofosbuvir (medicines used to treat hepatitis C infection) 
• ledipasvir/sofosbuvir (zdravili za zdravljenje okužbe s hepatitisom C),
• feeling weak, general feeling of being unwell 
• občutek šibkosti, splošno slabo počutje
If the patient misses a dose of Delstrigo within 12 hours of the time it is usually taken, the patient should take Delstrigo as soon as possible and resume the normal dosing schedule. 
Če bolnik izpusti odmerek zdravila Delstrigo in je od časa, ko ga vzame po navadi, minilo manj kot 12 ur, mora zdravilo Delstrigo vzeti čim prej in nato nadaljevati jemanje po običajnem urniku.
Delstrigo is a complete regimen taken as a single tablet for the treatment of HIV infection. 
Zdravilo Delstrigo je popolna shema za zdravljenje okužbe s HIV v eni sami tableti.
The antiviral activity of tenofovir against laboratory and clinical isolates of HIV-1 was assessed in T lymphoblastoid cell lines, primary monocyte/macrophage cells and peripheral blood lymphocytes. 
Protivirusno aktivnost tenofovirja proti laboratorijskim in kliničnim izolatom HIV-1 so ocenili v celičnih linijah limfoblastoidnih celic T, predvsem v monocitih/makrofagih in v limfocitih periferne krvi.
Tenofovir disoproxil was mutagenic in the in vitro mouse lymphoma assay and negative in an in vitro bacterial mutagenicity test (Ames test). 
Dizoproksiltenofovirat je bil mutagen v preizkusu mišjega limfoma in vitro, negativen pa je bil v testu mutagenosti pri bakterijah (Amesov test) in vitro.
Co-administration with the moderate CYP3A inducer rifabutin decreased doravirine concentrations (see Table 1). 
Sočasna uporaba z zmernim induktorjem CYP3A rifabutinom je zmanjšala koncentracijo doravirina (glejte preglednico 1).
If a patient misses a dose of Delstrigo by more than 12 hours, the patient should not take the missed dose and instead take the next dose at the regularly scheduled time. 
Če bolnik izpusti odmerek zdravila Delstrigo in je od časa, ko ga vzame po navadi, minilo več kot 12 ur, naj ne vzame izpuščenega odmerka, temveč naj namesto tega vzame naslednji odmerek ob rednem predvidenem času.
Film-coated tablets 30 film-coated tablets 90 (3 bottles of 30) film-coated tablets 
filmsko obložene tablete 30 filmsko obloženih tablet 90 (3 plastenke po 30) filmsko obloženih tablet
Autoimmune disorders (such as Graves' disease, autoimmune hepatitis, polymyositis, and GuillainBarré syndrome) have also been reported to occur in the setting of immune reactivation; however, the time to onset is more variable and can occur many months after initiation of treatment. 
V okviru imunske obnove so poročali tudi o pojavu avtoimunskih bolezni (npr. Gravesove bolezni, avtoimunski hepatitis, polimiozitisa in Guillan-Barréjevega sindroma), toda čas do začetka njihovega pojava je bolj spremenljiv in pojavijo se lahko več mesecev po uvedbi zdravljenja.
Immune reactivation syndrome 
Vnetni sindrom imunske obnove
• increased levels of creatine phosphokinase 
• zvišanje kreatin-fosfokinaze
None of the 24 subjects (11 in the immediate switch group, 13 in the delayed switch group) with baseline NNRTI mutations (RT K103N, G190A, or Y181C) experienced virologic failure through Week 48, or at time of discontinuation. 
Pri nobenem od 24 preiskovancev (11 v skupini s takojšnim prehodom, 13 v skupini z odloženim prehodom), ki so imeli v izhodišču z NNRTI povezane mutacije (RT K103N, G190A ali Y181C), se do 48. tedna oz. ob času prenehanja ni pojavil virološki neuspeh.
Doravirine steady state pharmacokinetics following administration of 100 mg once daily to HIV-1 infected subjects, based on a population pharmacokinetics analysis are provided below. 
Spodaj je prikazana farmakokinetika doravirina v stanju dinamičnega ravnovesja po uporabi 100 mg enkrat na dan pri preiskovancih, okuženih s HIV-1, na podlagi populacijske farmakokinetične analize.
• Keep the bottle tightly closed in order to protect from moisture. 
• Plastenko shranjujte dobro zaprto za zagotovitev zaščite pred vlago.
Doravirine is primarily metabolised and eliminated by the liver. 
Doravirin se v prvi vrsti presnovi in odstrani v jetrih.
< 200 cells/mm 
< 200 celic/mm
12 hours, skip the dose you missed and take the next one at the usual time. 
Toda če je do vašega naslednjega odmerka manj kot 12 ur, pozabljeni odmerek izpustite in vzemite naslednjega ob običajnem času.
HIV-1 isolates with the K65R substitution also showed reduced susceptibility to emtricitabine and lamivudine. 
Izolati HIV-1 s substitucijo K65R so bili tudi manj občutljivi na emtricitabin in lamivudin.
The clinically relevant effects noted were a reduction in red blood cell count and neutropenia. 
Opažena klinično pomembna učinka sta bila zmanjšanje števila eritrocitov in nevtropenija.
Rare hypomagnesaemia, lactic acidosis* 
Redki hipomagneziemija, laktacidoza*
HIV-1 isolates selected by tenofovir expressed a K65R substitution in HIV-1 RT and showed a 2-4 fold reduction in susceptibility to tenofovir. 
Izolati HIV-1, selekcionirani s tenofovirjem, so imeli v RT HIV-1 izraženo substitucijo K65R in so bili od 2- do 4-krat manj občutljivi za tenofovir.
Keep the bottle tightly closed in order to protect from moisture. 
Plastenko shranjujte dobro zaprto za zagotovitev zaščite pred vlago.
The median EC50 values of lamivudine were 60 nM (range: 20 to 70 nM), 35 nM (range: 30 to 40 nM), 30 nM (range: 20 to 90 nM), 20 nM (range: 3 to 40 nM), 30 nM (range: 1 to 60 nM), 30 nM (range: 20 to 70 nM), 30 nM (range: 3 to 70 nM), and 30 nM (range: 20 to 90 nM) against HIV-1 clades A-G and group O viruses (n = 3 except n = 2 for clade B) respectively. 
Mediana vrednost EC50 lamivudina proti HIV-1 kladov od A do G in virusom skupine O (n = 3 razen n = 2 za klad B) je bila 60 nM (razpon: 20-70 nM), 35 nM (razpon: 30-40 nM), 30 nM (razpon: 20-90 nM), 20 nM (razpon: od 3-40 nM ), 30 nM (razpon: od 1-60 nM), 30 nM (razpon: 20-70 nM), 30 nM (razpon: 3-70 nM) in 30 nM (razpon: 20-90 nM), v tem zaporedju.
This is because it has not been studied in pregnancy and it is not known if Delstrigo will harm your baby while you are pregnant. 
Uporaba zdravila Delstrigo med nosečnostjo namreč ni raziskana in tako ni znano, ali zdravilo Delstrigo med nosečnostjo škoduje otroku.
Persistent or worsening bone pain, pain in extremities, fractures, and/or muscular pain or weakness may be manifestations of proximal renal tubulopathy and should prompt an evaluation of renal function in at risk patients. 
Stalne kostne bolečine ali njihovo poslabšanje, bolečine v okončinah, zlomi in/ali boleče ali šibke mišice so lahko znaki proksimalne ledvične tubulopatije; če se pojavijo, je treba pri bolnikih s tveganjem nemudoma oceniti delovanje ledvic.
Expected:  doravirine 
Pričakovano:  doravirin
Doravirine pharmacokinetics are similar in healthy subjects and HIV-1-infected subjects. 
Farmakokinetika doravirina je pri zdravih osebah in preiskovancih, okuženih s HIV-1, podobna.
Lamivudine and tenofovir disoproxil are primarily excreted by the kidney. 
Lamivudin in dizoproksiltenofovirat se izločata predvsem skozi ledvice.
• telotristat ethyl (a medicine to treat diarrhea in people with carcinoid syndrome) 
• etiltelotristat (zdravilo za zdravljenje driske pri osebah s karcinoidnim sindromom),
MANUFACTURER(S) RESPONSIBLE FOR BATCH RELEASE 
A. PROIZVAJALEC (PROIZVAJALCI), ODGOVOREN (ODGOVORNI) ZA SPROŠČANJE SERIJ
At baseline, the median age of subjects was 31 years (range 18-70 years), 85 % were male, 52 % were non-white, 3 % had hepatitis B or C co-infection, 14 % had a history of AIDS, 21 % had HIV-1 RNA > 100,000 copies per mL, and 12 % had CD4 
V izhodišču je bila mediana starost preiskovancev 31 let (razpon: od 18 do 70 let), 85 % je bilo moških, 52 % je bilo nebelcev, 3 % so imeli sočasno okužbo z virusom hepatitisa B in/ali C, 14 % je imelo v anamnezi aids, 21 % je imelo HIV-1 RNA > 100.000 kopij/ml in 12 % jih je imelo število celic T CD4 < 200 celic/mm
Compared with subjects with normal renal function, the mean (% CV) tenofovir exposure increased from 2,185 (12 %) ng·h/mL in subjects with CrCl > 80 mL/min to respectively 3,064 (30 %) ng·h/mL, 6,009 (42 %) ng·h/mL and 15,985 (45 %) ng·h/mL in subjects with mild, moderate, and severe renal impairment. 
V primerjavi s preiskovanci z normalnim delovanjem ledvic se je povprečna (% KV) izpostavljenost tenofovirju od 2.185 (12 %) ng·h/ml pri preiskovancih z očistkom kreatinina > 80 ml/min pri preiskovancih z blago okvaro povečala na 3.064 ng·h/ml (30 %), pri tistih z zmerno okvaro na 6.009 ng·h/ml (42 %) in tistih s hudo okvaro ledvic na 15.985 ng·h/ml (45 %).
Baseline regimen = ritonavir or cobicistat-boosted PI (specifically atazanavir, darunavir, or lopinavir), or cobicistat-boosted elvitegravir, or NNRTI (specifically efavirenz, nevirapine, or rilpivirine), each administered with two NRTIs. 
Izhodiščna shema = zaviralec proteaz (specifično atazanavir, darunavir ali lopinavir), ojačen z ritonavirjem ali kobicistatom, ali elvitegravir, ojačen s kobicistatom, ali NNRTI (specifično efavirenz, nevirapin ali rilpivirin), vsi uporabljeni z dvema NRTI.
Oral Contraceptives 
Peroralni kontraceptivi
Administration of lamivudine in animal toxicity studies at high doses was not associated with any major organ toxicity. 
Uporaba velikih odmerkov lamivudina v študijah toksičnosti na živalih ni bila povezana s toksičnimi učinki na katerega od pomembnih organov.
HIV-1 isolates from patients (n = 20) whose HIV-1 expressed a mean of 3 zidovudine associated RT amino acid substitutions (M41L, D67N, K70R, L210W, T215Y/F, or K219Q/E/N) showed a 3.1-fold decrease in the susceptibility to tenofovir. 
Izolati HIV-1 bolnikov (n = 20), katerih HIV-1 je imel izražene povprečno 3 z zidovudinom povezane aminokislinske substitucije RT (M41L, D67N, K70R, L210W, T215Y/F ali K219Q/E/N), so imeli 3,1-krat manjšo občutljivost za tenofovir.
Refill your prescription or talk to your doctor before your Delstrigo is all gone. 
Zdravilo prevzemite v lekarni ali se posvetujte z zdravnikom, še preden vam zmanjka zdravila Delstrigo.
In DRIVE-FORWARD, 766 subjects were randomised and received at least 1 dose of either doravirine 100 mg or darunavir + ritonavir 800+100 mg once daily, each in combination with emtricitabine/tenofovir disoproxil (FTC/TDF) or abacavir/lamivudine (ABC/3TC) selected by the investigator. 
V preskušanju DRIVE-FORWARD je bilo randomiziranih 766 preiskovancev in prejeli so vsaj 1 odmerek bodisi 100 mg doravirina bodisi kombinacije darunavirja + ritonavirja 800 + 100 mg enkrat na dan, oboje v kombinaciji z emtricitabinom/dizoproksiltenofoviratom (FTC/TDF) ali z abakavirjem/lamivudinom (ABC/3TC) po izbiri raziskovalca.
If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse. 
Če imate kakršna koli dodatna vprašanja o uporabi tega zdravila, se posvetujte z zdravnikom, farmacevtom ali medicinsko sestro.
Mean CD4 change from baseline 
Povprečna sprememba CD4 od izhodišča
Uncommon myalgia, arthralgia, rhabdomyolysis* muscular weakness* 
Občasni mialgija, artralgija, rabdomioliza* †, šibkost mišic*
The K70E substitution selected clinically by tenofovir disoproxil results in reduced susceptibility to abacavir, didanosine, emtricitabine, lamivudine, and tenofovir. 
Substitucija K70E, klinično selekcionirana z dizoproksiltenofoviratom, zmanjša občutljivost za abakavir, didanozin, emtricitabin, lamivudin in tenofovir.
• decreased levels of magnesium 
• znižanje koncentracije magnezija
This adverse reaction may occur as a consequence of proximal renal tubulopathy. 
Ta neželeni učinek se lahko pojavi kot posledica proksimalne ledvične tubulopatije.
Joint or muscle pain or muscle weakness may also occur. 
Pojavijo se lahko tudi bolečine v sklepih ali mišicah ali šibkost mišic.
Medicinal Product by Therapeutic Area 
Zdravila po terapevtskih področjih
• decreased number of white blood cells in your blood (neutropenia) 
• zmanjšanje števila belih krvnih celic (nevtropenija)
Consistent results were seen for the comparison at Study Week 24 in each treatment group. 
V 24. tednu so bili rezultati med obema terapevtskima skupinama primerljivi.
Pharmacokinetic parameters of tenofovir were determined following administration of a single dose of tenofovir disoproxil 245 mg to 40 non-HIV infected adult subjects with varying degrees of renal impairment defined according to baseline CrCl (normal renal function when CrCl > 80 mL/min; mild with CrCl = 50-79 mL/min; moderate with CrCl = 30-49 mL/min and severe with CrCl = 10-29 mL/min). 
Farmakokinetične parametre tenofovirja so določili po uporabi enkratnega odmerka 245 mg dizoproksiltenofovirata pri 40 osebah, ki niso bile okužene s HIV in so imele glede na izhodiščni očistek kreatinina različno stopnjo okvare ledvic (normalno delovanje ledvic: očistek kreatinina > 80 ml/min, blaga okvara = 50-79 ml/min, zmerna okvara = 30-49 ml/min in huda okvara = 10-29 ml/min).
Because a negligible amount of lamivudine was removed via (4-hour) haemodialysis, continuous ambulatory peritoneal dialysis, and automated peritoneal dialysis, it is not known if continuous haemodialysis would provide clinical benefit in a lamivudine overdose event. 
Hemodializa (4-urna), stalna ambulantna peritonealna dializa in avtomatska peritonealna dializa so odstranile le zanemarljivo količino lamivudina, zato ni znano, ali bi stalna hemodializa v primeru prevelikega odmerjanja lamivudina klinično koristila.
There are limited data available on the use of doravirine, lamivudine, and tenofovir disoproxil in patients aged 65 years and over. 
Podatkov o uporabi doravirina, lamivudina in dizoproksiltenofovirata pri bolnikih, starih 65 let ali več, je malo.
Film-coating Carnauba wax (E903) Hypromellose (E464) Iron oxide yellow (E172) Lactose monohydrate Titanium dioxide (E171) Triacetin (E1518) 
Filmska obloga karnauba vosek (E903) hipromeloza (E464) rumeni železov oksid (E172) laktoza monohidrat titanov dioksid (E171) triacetin (E1518)
Reproductive toxicity studies in rats and rabbits showed no effects on mating, fertility, pregnancy or foetal parameters. 
Rezultati študij o vplivu na sposobnost razmnoževanja pri podganah in kuncih niso pokazali učinkov na parametre parjenja, plodnosti, brejosti ali ploda.
This is achieved by adding one 100 mg tablet of doravirine (as a single agent), to be taken approximately 12 hrs apart from the dose of Delstrigo (see section 4.5). 
To dosežemo z dodatkom 100-mg tablete doravirina (kot samostojnega zdravila), ki jo bolnik vzame približno 12 ur po odmerku zdravila Delstrigo (glejte poglavje 4.5).
Patients with moderate or severe renal impairment require a dose interval adjustment of lamivudine and tenofovir disoproxil that cannot be achieved with the combination tablet (see sections 4.4 and 5.2). 
Pri bolnikih z zmerno ali hudo okvaro ledvic je treba prilagoditi interval odmerjanja lamivudina in dizoproksiltenofovirata, to pa s kombinirano tableto ni mogoče (glejte poglavji 4.4 in 5.2).
Doravirine has not been studied in subjects with severe hepatic impairment (Child-Pugh score C) (see section 4.2). 
Doravirin ni raziskan pri bolnikih s hudo okvaro jeter (Child-Pugh C) (glejte poglavje 4.2).
Difference (95 % CI) 
Razlika med zdravljenjema (95 % IZ)
Expected: ↑ tenofovir 
Pričakovano: ↑ tenofovir
The Phase 3 studies, DRIVE-FORWARD and DRIVE-AHEAD, included previously untreated patients (n = 747) where the following NNRTI substitutions were part of exclusion criteria: L100I, K101E, K101P, K103N, K103S, V106A, V106I, V106M, V108I, E138A, E138G, E138K, E138Q, E138R, V179L, Y181C, Y181I, Y181V, Y188C, Y188H, Y188L, G190A, G190S, H221Y, L234I, M230I, M230L, P225H, F227C, F227L, F227V. 
V študijah 3. faze DRIVE-FORWARD in DRIVE-AHEAD so bili vključeni predhodno še nezdravljeni bolniki (n = 747); med merili za nevključitev v teh dveh študijah so bile naslednje z NNRTI povezane substitucije: L100I, K101E, K101P, K103N, K103S, V106A, V106I, V106M, V108I, E138A, E138G, E138K, E138Q, E138R, V179L, Y181C, Y181I, Y181V, Y188C, Y188H, Y188L, G190A, G190S, H221Y, L234I, M230I, M230L, P225H, F227C, F227L, F227V.
The efficacy of switching from a baseline regimen consisting of two nucleoside reverse transcriptase inhibitors in combination with a ritonavir- or cobicistat-boosted PI, or cobicistat-boosted elvitegravir, or an NNRTI to Delstrigo was evaluated in a randomized, open-label trial (DRIVE-SHIFT), in virologically suppressed HIV-1 infected adults. 
Učinkovitost prehoda z izhodiščne sheme (ki je obsegala dva nukleozidna zaviralca reverzne transkriptaze v kombinaciji z zaviralcem proteaz, ojačenim z ritonavirjem ali kobicistatom, ali z elvitegravirjem, ojačenim s kobicistatom, ali z nekim NNRTI) na zdravilo Delstrigo so ocenili v randomiziranem, odprtem preskušanju (DRIVE-SHIFT) pri virološko suprimiranih odraslih, okuženih s HIV-1.
Subjects were randomized to either switch to Delstrigo at baseline [N= 447, Immediate Switch Group (ISG)], or stay on their baseline regimen until Week 24, at which point they switched to Delstrigo [N= 223, Delayed Switch Group (DSG)]. 
Preiskovance so randomizirali bodisi na prehod na zdravilo Delstrigo izhodiščno [N = 447, skupina s takojšnjim prehodom (ISG - Immediate Switch Group)] bodisi na nadaljevanje izhodiščne sheme do 24. tedna, ko so prešli na zdravilo Delstrigo [N = 223, skupina z odloženim prehodom (DSG - Delayed Switch Group)].
What Delstrigo looks like and contents of the pack Delstrigo is available as a yellow, oval-shaped, film-coated tablet, and is debossed with the corporate logo and 776 on one side and plain on the other side. 
Zdravilo Delstrigo je na voljo v obliki rumenih filmsko obloženih tablet ovalne oblike z vtisnjenim logotipom podjetja in oznako 776 na eni strani in brez oznake na drugi strani.
Pharmacotherapeutic group: Antivirals for systemic use, ATC code: J05AR24 
Oznaka ATC: J05AR24
Blood and lymphatic systems disorders Uncommon neutropenia*, anaemia*, thrombocytopenia* 
Bolezni krvi in limfatičnega sistema Občasni nevtropenija*, anemija*, trombocitopenija*
In the DRIVE-SHIFT clinical trial, no subjects developed genotypic or phenotypic resistance to DOR, 3TC, or TDF during the initial 48 weeks (immediate switch, N=447) or 24 weeks (delayed switch, N=209) of treatment with Delstrigo. 
V kliničnem preskušanju DRIVE-SHIFT se med zdravljenjem z zdravilom Delstrigo pri nobenem preiskovancu v prvih 48 tednih (takojšen prehod, N=447) ali 24 tednih (odložen prehod, N=209) ni pojavila ne genotipska ne fenotipska odpornost proti DOR, 3TC ali TDF.
Due to the tenofovir disoproxil component of doravirine/lamivudine/tenofovir disoproxil, use of the product should be avoided with concurrent or recent use of nephrotoxic medicinal products. 
Zaradi dizoproksiltenofovirata v kombinaciji doravirin/lamivudin/dizoproksiltenofovirat se je uporabi kombinacije treba izogniti v primeru trenutne ali nedavne uporabe nefrotoksičnih zdravil.
Each carton contains a high density polyethylene (HDPE) bottle with a polypropylene child-resistant closure with silica gel desiccants. 
Vsaka škatla vsebuje plastenko iz polietilena velike gostote (HDPE) s polipropilensko, za otroke varno zaporko in silicijevim dioksidom kot sušilom.
Renal and urinary disorders Uncommon increased creatinine*, proximal renal tubulopathy (including Fanconi syndrome)* 
Bolezni sečil Občasni zvišanje kreatinina*, proksimalna ledvična tubulopatija (vključno s Fanconijevim sindromom)*
Delstrigo 100 mg/300 mg/245 mg film-coated tablets. 
Delstrigo 100 mg/300 mg/245 mg filmsko obložene tablete
Oral carcinogenicity studies in rats and mice only revealed a low incidence of duodenal tumours at an extremely high-dose in mice. 
Rezultati študij peroralne kancerogenosti pri podganah in miših so pokazali majhno pojavnost tumorjev dvanajstnika ob uporabi izredno velikega odmerka pri miših.
If you are not sure, talk to your doctor, pharmacist, or nurse before taking Delstrigo. 
Če ste negotovi, se pred začetkom jemanja zdravila Delstrigo posvetujte z zdravnikom, farmacevtom ali medicinsko sestro.
Lamivudine Cmax decreased by 19 % with a high fat meal, while AUC was not significantly affected. 
Zelo masten obrok je zmanjšal Cmax lamivudina za 19 % in ni pomembno vplival na AUC.
Tenofovir disoproxil is an acyclic nucleoside phosphonate diester analog of adenosine monophosphate. 
Dizoproksiltenofovirat je acikličen nukleozidni fosfonatni diestrski analog adenozinmonofosfata.
Tenofovir diphosphate is a weak inhibitor of mammalian DNA polymerases α, β, and mitochondrial DNA polymerase γ. 
Tenofovirdifosfat je šibek zaviralec DNA polimeraz α in β pri sesalcih ter mitohondrijske DNA polimeraze γ.